Estimates of the prevalence of HIV-1 drug resistance in children are important for assessing requirements for available drug classes and modeling the spread of resistance. There is a paucity of relevant studies and recommendations in this challenging group.
Abstract

Background
Estimates of the prevalence of HIV-1 drug resistance in children are important for assessing requirements for available drug classes and modeling the spread of resistance. There is a paucity of relevant studies and recommendations in this challenging group.
Methods
We therefore reviewed HIV-1 genotypes from 200/979 (20%) HIV-infected children in the UK CHIPS cohort (343 resistance tests).
Results
3/44 samples had major primary resistance mutations before ART. The proportion of children with a resistance test and HIV-1 VL > 1,000 c/ml increased over time (6% in 1998 -23% in 2004 ). 3-class resistance was noted in 42 samples (14.1%) . 35 tests were performed in children with previous exposure to HAART, but who had stopped treatment 13 (0.1-135) weeks previously.
Mutations decreased significantly with time off treatment (r=-0.4; p=0.02).
Conclusions
Our study highlights underutilization of resistance testing and the need for prompt genotyping after drug discontinuation. This may lead to an underestimation of the burden of HIV-1 resistance. Care for HIV-1-infected infants and children may be improved with larger surveillance data and child-specific guidelines for resistance testing.
Introduction
The treatment of human immunodeficiency virus type 1 (HIV-1) infection with highly active antiretroviral therapy (HAART) significantly reduces the levels of viral RNA in plasma and lymphoid tissue [1] [2] [3] . This reduction is associated with a marked decline in HIV-1-related morbidity and mortality [4] . Failure to respond to HAART with virological rebound may be associated with the emergence of drugresistant virus [5] . Viral gene sequence-based resistance testing or genotyping may be used to guide subsequent treatment choices. More than 50 drug resistance-associated mutations have been identified that, either alone or in combination, confer variable resistance to one or more drugs within a specific class [6] . Thus, HIV genotyping may serve as an important diagnostic tool for optimizing therapy in individuals with drug-resistant infection [7] .
Significant variations can influence the emergence of drug resistance-associated mutations under selective pressure from HAART. These differences may reflect high peak viral loads following primary infection, delayed attainment of virologic set point during clinical latency in the first years following vertical transmission [8] , and transmission of HIV-1 with primary resistance to HAART [9] . It is important to undertake population-based estimations of drug resistance in HIV-1-infected infants and children.
The aims of this study were therefore to summarize the total number of resistance tests performed on a large group of HIV-1-infected children and young people in the UK within the Collaborative HIV in Paediatric Study (CHIPS) cohort, and to document how the number of resistance tests undertaken for routine clinical purposes changed over time. We investigated the proportion of samples suggesting at least one major protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI) or nucleoside reverse transcriptase inhibitor (NRTI) mutation, or with documented resistance to all three main drug classes.
Finally, we calculated the prevalence of documented resistance as a proportion of the number of children under follow-up who were receiving HAART and as a proportion of the number under follow-up failing therapy.
Methods
Children and young people included in this study were participants in the UK and Ireland Collaborative Paediatric HIV Study (CHIPS) cohort [www.chipscohort.ac.uk] . This is a multi-centre cohort of HIV-1-infected children including clinical, laboratory and treatment data on children from 43 centres, representing around 85% of all HIV-1-infected children reported to the National Study of HIV in Pregnancy and Childhood (NSHPC) [http://www.bhiva.org/chiva/protocols/study.html]. Study methods have been described elsewhere [10] . Age varied from under one to 20 years.
Children in CHIPS under follow-up in the UK between 1st January 1998 and 31st December 2004 were included to correspond with the dates at any time point for which resistance tests were available. Children were defined as failing HAART in a particular calendar year if they had at least one viral load measurement during the year >1,000 copies/ml after receiving therapy for >16 weeks.
The proportion of samples and of HIV-1-infected children demonstrating resistance to at least one of the three main drug (PI, NNRTI & NRTI) classes on at least one occasion was estimated by year and stratified by whether the child had ever received antiretroviral therapy at the time of the resistance test.
We considered at which time point during a child's care the resistance test was performed, concentrating on treatment status (naïve, currently receiving HAART, not currently receiving therapy but with previous exposure to HAART) and the association with individual drug mutations. This analysis was repeated, but to only include those children who had been failing HAART during the year of interest.
Information on resistance testing was obtained from the UK HIV Drug Resistance Database, which consists of routinely performed HIV-1 drug resistance tests in adults and children within the UK [11] . Resistance data were matched to CHIPS subjects using patient identifiers, including clinic number and date of birth. Resistance was defined as the detection of one or more major mutations in the 2005 International AIDS Society-USA guidelines [12] , plus selected additional mutations (in reverse transcriptase, any mutation at G190 or T215; in protease, V32I and I47V/A in combination, or seven or more minor lopinavir mutations). 
Results
Nine hundred and seventy nine children in the CHIPS
Underutilisation of drug resistance testing at the time of virological rebound
We next considered resistance tests at the time of virological failure, considering the number of children who had a genotype performed when failing therapy according to calendar year. In 1998, 9 (5.7%) of 159 children failing ART had a resistance test performed [ Figure 1 ]. This proportion gradually increased but by 2004 genotypes were still requested in only 23.3% (47 of 202) of HIV-1-infected children failing therapy.
Drug resistance in 'naïve' children
Of the total of 44 tests performed in naïve children prior to the commencement of HAART, the median (range) viral load and CD4 percentage at the time of the test was 5.4 (4.0, 7.0) log copies/ml and 17% (0%, 39%) respectively. The median (range) age of children at the time of the test was 4.9 (0.0, 17.0) years. Three samples (6.8%) contained major primary resistance mutations to NRTI's and also to NNRTI's in one child. None of the biological mothers of the three children had documented evidence of antenatal prophylaxis with ART to reduce vertical transmission.
Resistance in treated children
When considering the resistance tests performed in antiretroviral experienced children, the percentage of samples containing at least one major NRTI mutation Of the 299 samples taken in ART-experienced patients, 76 (25.4%) were performed in teenagers (aged 13 years or older). There were differences in the observed resistance mutations in teenagers compared to adults, perhaps related to a longer potential ART-exposure time amongst older children. 30 (13.5%), 51 (22.9%), 110 (49.3%) and 32 (14.4%) of those aged <13 years had evidence of resistance to 0, 1, 2 and 3 drug classes, respectively. For the teenagers, these figures were 7 (9.2%), 36 (47.4%), 23 (30.3%) and 10 (13.2%) respectively.
Major drug class mutations in 264 tests among children receiving HAART
Of the 264 tests performed in children receiving HAART, the median (range) viral load and CD4 percentage at the time of the test was 4.3 (1.7, 6 .0; 20 with a missing viral load) log copies/ml and 20% (0%, 56%; 25 missing) respectively.
Children had been exposed to a median (range) of 5 (1, 15) drugs; 187 (70.8%) had received at least one PI and 188 (71.2%) at least one NNRTI. The median (range) length of exposure to ART at the time of the test was 3.8 (0.1, 12.7) years. The median (range) age at the time of the test was 9.6 (0.5, 20.1) years.
The most common NRTIs that children had ever been exposed to were the F mutation, 5 the I mutation, 2 the N mutation, and one sample each for H, X and C. For the 190 position, 50 samples had the A mutation, 5 the S mutation, 3 the E mutation and 1 sample had the N mutation. The most commonly detected specific mutations on the protease gene included D30N (29; 11.0%), M46I/L (43; 16.3%) and L90M (39; 14.8%).
Major drug class mutations in 35 tests among children with previous but not current exposure to HAART
Of the 35 tests performed in HIV-1-infected children not currently receiving therapy but with previous exposure to HAART, the median (range) viral load, CD4 percentage and age at the time of the test was 4.6 (2.7, 6.4) log copies/ml, 19% (1%, 38%) and 10.5 (0.3, 20. 2) years respectively. Children had been 
Discussion
There are over 20 available antiretroviral drugs from 4 classes to treat HIV-1-infected infants and children using triple or quadruple-combination HAART.
Drug resistance commonly occurs secondary to a number of factors that are distinct from HIV-1-infected adults receiving HAART, and tend to be most prominent in the youngest children. These include a lack of age-appropriate formulations; a paucity of pharmacokinetic, safety and efficacy data resulting in sub-therapeutic concentrations of active drug within plasma; high peak viral loads and prolonged time to attain a virologic set point during clinical latency in the first few years following vertical transmission [8] , and transmission of HIV-1 with primary resistance as a result of maternal treatment/prophylaxis [9] . These concerns were highlighted by Menson and co-workers who documented considerable under-dosing of antiretrovirals in the UK and Ireland based on current best evidence in HIV-infected infants and children [13] . Poor adherence is often further compromised during adolescence [14] . Resistance to a drug may result in cross-resistance to other drugs within the same class, thereby limiting the long-term efficacy of treatment and future therapeutic options [15] . These difficulties highlight the importance of population-based surveys of drug resistance during childhood and adolescence. The CHIPS database represents a resource for audit and clinical research reflecting the largest published study of HIV-1 drug resistance in paediatrics using single test results per calendar unit, in a treatment-experienced population.
Our study may underestimate the burden of HIV-1 resistance in the treated population. Only 21% of those with a detectable viral load measurement whilst receiving HAART had a resistance test undertaken. Resistance testing is rarely requested in infants and children with detectable viral load who eventually do not switch therapy. Not all resistance tests may have been included in the final analysis because of a failure to match records due to inaccurate identifiers.
Furthermore resistance may emerge at viral loads below the levels required for successful testing [16] . In addition, among those who stopped therapy prior to their resistance test, the median time from stopping all HAART to the time of the resistance test was 13.6 weeks. As this period increased, the number of drugrelated mutations detected decreased, contributing further to an underestimation of resistance prevalence in this population. This observation highlights the need for clinicians caring for HIV-1-infected children to request resistance tests immediately after drug discontinuation before potential reversion to wild type virus as the major species.
Genotypic resistance evaluation has become standard of care according to most current guidelines on ART management when changing therapy in HIV-infected adults failing HAART [5, 17] . The British HIV Association (BHIVA) recommends resistance testing at the time of switching therapy in treatment-experienced patients, and also recommends testing at the time of HIV diagnosis and at the time of commencing HAART [http://www.bhiva.org/].This is despite variable evidence from randomized trials comparing the subsequent virological response following ART change guided by HIV resistance testing compared with regimens selected by antiretroviral exposure history [18, 19] . Guidelines on resistance testing in HIV-1-infected infants and children are limited by a paucity of studies reflecting smaller cohort sizes, and no trials apart from PERA -which demonstrated no virological benefit from regimens selected after resistance testing [20] . This cohort review cannot assess the potential benefit of genotyping in antiretroviral-experienced infants and children compared to regimens selected by antiretroviral exposure history. However given the overall increase in prevalence of HIV-1 resistance mutations an extrapolation of BHIVA guidelines on HIV resistance to HIV-1-infected infants and children could be considered. This is reflected in the increased prevalence of primary HIV-1 resistance mutations among HIV-1-infected adults [11] and the detection of primary mutations in vertically-infected infants born to mothers with antiretroviral exposure [9] . Detection of primary HIV-1 resistance mutations in 3 infants from this study lends support for resistance testing in all newly diagnosed infants. This last observation contrasts with findings from our group which reported in 2002 that no primary HIV-1 resistance mutations were detected at baseline in protease or RT among 113 children [21] .
Extensive 3-class resistance was noted in a significant proportion of resistance tests (12%), which is higher than the level observed in adults in the UK (approximately 5%) [22] , and may limit future therapeutic options for adolescents being transferred to adult clinics. Resistance to NRTIs may reflect exposure to Management of HIV-1-infected children will become increasingly complex as more children develop extensive multi-class resistant viruses. These concerns may be addressed with larger paediatric surveillance studies and the development of guidelines on resistance testing. We recommend that resistance testing is obtained in all newly diagnosed children regardless of age at diagnosis and whether or not their mother received ART during pregnancy. In addition, as for HIV-infected adults, testing should be considered during virological failure. Thank you for accepting the above manuscript for publication in PIDJ. Naturally we are delighted that the reviewers and editors find this a topical and important subject to inform the readership. We have submitted changes to the manuscript to reflect the very helpful suggestions of the reviewers. In addition a 'point by point' response is supplied in this correspondence. On P.10 and 11 we have added the following paragraph: 'Of the 299 samples taken in ART-experienced patients, 76 (25.4%) were performed in teenagers (aged 13 years or older). There were differences in the observed resistance mutations in teenagers compared to adults, perhaps related to a longer potential ARTexposure time amongst older children. 30 (13.5%), 51 (22.9%), 110 (49.3%) and 32 (14.4%) of those aged <13 years had evidence of resistance to 0, 1, 2 and 3 drug classes, respectively. For the teenagers, these figures were 7 (9.2%), 36 (47.4%), 23 (30.3%) and 10 (13.2%) respectively'.
2. The legend to figure 4 is rather misleading and should be corrected.
The legend now reads: 'Number of major IAS mutations observed in each resistance test sample taken after the child had stopped antiretroviral therapy, according to the time since ART was stopped'
